IP Library › Patent Application 18983163
Patent Application
App. No. 18/983,163

CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/983,163
Abstract

Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.

Claims (42)

1 - 31 . (canceled)

32 . A compound having the formula (XXXI):

wherein:

T 2 is a group comprising a nucleoside, a nucleotide, a monomeric subunit, a reactive ester, a linker, a cleavable moiety or an oligomeric compound.

33 - 37 . (canceled)

38 . The compound of claim 32 , wherein T 2 a group comprising an oligomeric compound, and wherein the oligomeric compound is a modified oligonucleotide.

39 - 59 . (canceled)

60 . A method comprising administering the compound of claim 32 to an animal.

61 . A method of treating a metabolic or cardiovascular disorder comprising administering the compound of claim 32 to a subject in need thereof.

62 . (canceled)

63 . A compound having the formula (XXXII):

wherein:

T 2 is a group comprising a nucleoside, a nucleotide, a monomeric subunit, a reactive ester, a linker, a cleavable moiety or an oligomeric compound.

64 - 68 . (canceled)

69 . The compound of claim 63 , wherein T 2 is a group comprising an oligomeric compound, and wherein the oligomeric compound is a modified oligonucleotide.

70 - 90 . (canceled)

91 . A method f-comprising administering the compound of claim 63 to an animal.

92 . A method of treating a metabolic or cardiovascular disorder comprising administering the compound of claim 63 to a subject in need thereof.

93 . (canceled)

94 . A compound having the formula(XXXVIII):

wherein:

T 2 is a group comprising a nucleoside, a nucleotide, a monomeric subunit, a reactive ester, a linker, a cleavable moiety or an oligomeric compound.

95 - 99 . (canceled)

100 . The compound of claim 94 , wherein T 2 is a group comprising an oligomeric compound, and wherein the oligomeric compound is a modified oligonucleotide.

101 - 121 . (canceled)

122 . A method comprising administering the compound of claim 94 to an animal.

123 . A method of treating a metabolic or cardiovascular disorder comprising administering the compound of claim 94 to a subject in need thereof.

124 . (canceled)

125 . A compound having the formula (XL):

wherein:

T 2 is a group comprising a nucleoside, a nucleotide, a monomeric subunit, a reactive ester, a linker, a cleavable moiety or an oligomeric compound.

126 - 130 . (canceled)

131 . The compound of claim 125 , wherein T 2 is a group comprising an oligomeric compound, and wherein the oligomeric compound is a modified oligonucleotide.

132 - 152 . (canceled)

153 . A method comprising administering the compound of claim 125 to an animal.

154 . A method of treating a metabolic or cardiovascular disorder comprising administering the compound of claim 125 to a subject in need thereof.

155 . (canceled)

156 . A method comprising administering a conjugated antisense compound to an animal, wherein the conjugated antisense compound comprises a modified oligonucleotide having a gapmer sugar motif and a conjugate comprising a GalNAc.

157 - 160 . (canceled)

161 . The method of claim 156 , wherein the conjugate comprises the following structure:

162 . The method of claim 156 , wherein the conjugate comprises the following structure:

163 - 296 . (canceled)